Amgen

Eli Lilly

Alnylam Pharmaceuticals

Vertex Pharmaceuticals

Cytokinetics

Rocket Pharma

BridgeBio Pharma Inc

Crinetics Pharmaceuticals Inc

Medtronic

Insulet

Tema Obesity & Cardiometabolic ETF

HRTS is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive.

The Tema Obesity & Cardiometabolic ETF is a new actively managed fund focusing on the obesity treatment market. The investment strategy includes a mix of cash flow-positive companies, high-growth companies, and start-ups with promising technology. An interview with the PM increased my understanding and confidence in the portfolio construction and strategy.

HRTS: Generating Alpha In Obesity Treatment

Roundhill GLP-1 & Weight Loss ETF

Amplify Weight Loss Drug & Treatment ETF

Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

By 2030, the weight loss drug market is estimated to reach a significant size, attracting many competitors due to the high prevalence of obesity-related comorbidities. The Tema Obesity & Cardiometabolic ETF offers exposure to leading biotech and pharma companies in the anti-obesity drugs market, focusing on GLP-1 medicines. HRTS outperformed the market since its inception, with a focus on mid-cap pharma businesses and a moderate risk profile, making it a favorable investment in the expanding cardiometabolic drugs market.

HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside

Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.

Play These New ETFs to Tap Lucrative Weight Loss Drug Market

iShares Nasdaq Biotechnology ETF

Health Care Select Sector SPDR Fund

Weight loss has long been a challenge for many people, me included. Indeed, there are an estimated 1 billion individuals living with obesity, and the Obesity World Atlas estimates this could rise to 1.9 billion by 2035.

Fighting Obesity Using ETFs

Amplify Global Cloud Technology ETF

Amplify Alternative Harvest ETF

Amplify US Alternative Harvest ETF

AdvisorShares Pure US Cannabis ETF

MUSQ Global Music Industry ETF

VanEck Vectors Pharmaceutical ETF

First Trust Cloud Computing ETF

VanEck Vectors Semiconductor ETF

iShares PHLX Semiconductor ETF

Digging into the first quarter's earnings season allows us to uncover the winning themes of the period as captured by ETFs.

Thematic ETF Winners of the Q1 2024 Earnings Season

Ascendis Pharma

DexCom

Edwards Lifesciences

iShares U.S. Pharmaceuticals ETF

Novo Nordisk

SPDR S&P 500 ETF Trust

Viking Therapeutics

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

Tema ETFs has launched a new exchange traded fund (ETF) that tracks popular drugmakers like Novo Nordisk and Eli Lilly , aiming to tap into growing demand for their weight-loss and diabetes drugs.

Tema ETFs hops on weight-loss drug frenzy with its new cardiovascular fund

News for Tema Obesity & Cardiometabolic ETF ETF (HRTS)